Engineered retargeting to overcome systemic delivery challenges in oncolytic adenoviral therapy.
作者信息
Leparc Louise, Wakimoto Hiroaki
机构信息
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Laboratory of Nervous System Disorders and Therapy, GIGA Institute, University of Liège, 4000 Liège, Belgium.
出版信息
Mol Ther Oncol. 2025 Jun 6;33(2):201005. doi: 10.1016/j.omton.2025.201005. eCollection 2025 Jun 18.
Abstract
摘要
相似文献
1
Engineered retargeting to overcome systemic delivery challenges in oncolytic adenoviral therapy.
Mol Ther Oncol. 2025 Jun 6;33(2):201005. doi: 10.1016/j.omton.2025.201005. eCollection 2025 Jun 18.
2
PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Cancer Immunol Res. 2015 Jul;3(7):751-63. doi: 10.1158/2326-6066.CIR-14-0124-T. Epub 2015 Feb 19.
3
Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
J Virol. 2018 Feb 26;92(6). doi: 10.1128/JVI.02132-17. Print 2018 Mar 15.
4
Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
J Virol. 2018 Feb 26;92(6). doi: 10.1128/JVI.02122-17. Print 2018 Mar 15.
5
Oncolytic adenoviruses - selective retargeting to tumor cells.
Oncogene. 2005 Nov 21;24(52):7775-91. doi: 10.1038/sj.onc.1209044.
6
A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00067-17. Print 2017 May 15.
7
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
Nat Commun. 2019 Jul 19;10(1):3236. doi: 10.1038/s41467-019-11137-5.
8
Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
Viruses. 2016 Feb 26;8(3):63. doi: 10.3390/v8030063.
9
Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor.
Biomater Adv. 2023 Jan;144:213208. doi: 10.1016/j.bioadv.2022.213208. Epub 2022 Nov 23.
10
Adenovirus retargeting to surface expressed antigens on oral mucosa.
J Gene Med. 2010 Apr;12(4):365-76. doi: 10.1002/jgm.1447.
本文引用的文献
1
Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin.
Mol Ther Oncol. 2025 Mar 15;33(2):200967. doi: 10.1016/j.omton.2025.200967. eCollection 2025 Jun 18.
2
Mesothelin: An Immunotherapeutic Target beyond Solid Tumors.
Cancers (Basel). 2022 Mar 18;14(6):1550. doi: 10.3390/cancers14061550.
3
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
Nano Res. 2022;15(5):4137-4153. doi: 10.1007/s12274-021-4031-6. Epub 2022 Feb 14.
4
Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.
Cell Chem Biol. 2022 Mar 17;29(3):451-462.e8. doi: 10.1016/j.chembiol.2021.10.012. Epub 2021 Nov 12.
5
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Cells. 2021 Apr 22;10(5):978. doi: 10.3390/cells10050978.
6
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
JCI Insight. 2018 Apr 5;3(7). doi: 10.1172/jci.insight.99573.
7
CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer.
Oncotarget. 2017 Jun 2;8(44):76044-76056. doi: 10.18632/oncotarget.18340. eCollection 2017 Sep 29.
8
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery.
J Control Release. 2016 Sep 10;237:78-88. doi: 10.1016/j.jconrel.2016.07.004. Epub 2016 Jul 4.
9
Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library.
Mol Ther. 2013 Jan;21(1):139-48. doi: 10.1038/mt.2012.205. Epub 2012 Oct 2.
10
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.
Cancer Gene Ther. 2010 Apr;17(4):289-97. doi: 10.1038/cgt.2009.67. Epub 2009 Oct 30.
Zotero 插件